apodev 5 mg/ml solución para perfusión efg
evolan pharma ab - apomorfina hidrocloruro hemihidrato - soluciÓn para perfusiÓn - 5 mg/ml inyectable 20 ml - apomorfina hidrocloruro hemihidrato 5 mg - apomorfina
urinorm 100 mg comprimidos
evolan pharma ab - benzbromarona - comprimido - 100 mg - benzbromarona 100 mg - benzbromarona
clindamicina aristo 100 mg ovulos
aristo pharma gmbh - clindamicina fosfato - Óvulo - 100 mg - clindamicina fosfato 100 mg - clindamicina
apodev 5mg/ml 1 vial de 20ml solucion para perfusion efg
apodev 5 mg/ml solucion para perfusion efg, 5 viales de 20 ml
bemolan 400 mg comprimidos masticables
nycomed pharma, s.a - magaldrato - excipientes: sorbitol - antiÁcidos - combinaciones y complejos de compuesto de aluminio, calcio y magnesio - magaldrato
moxifloxacino bluepharma 400 mg comprimidos recubiertos con pelicula efg
bluepharma industria farmaceutica s.a. - moxifloxacino hidrocloruro - comprimido recubierto con pelÍcula - 400 mg - moxifloxacino hidrocloruro 400 mg - moxifloxacino
revolade
novartis europharm limited - eltrombopag - púrpura, trombocitopénica, idiopática - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 y 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 y 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.
moxifloxacino kern pharma 400 mg comprimidos recubiertos con pelicula efg
kern pharma s.l. - moxifloxacino hidrocloruro - comprimido recubierto con pelÍcula - 400 mg - moxifloxacino hidrocloruro 400 mg - moxifloxacino
bemolan 2000 mg gel oral
takeda farmaceutica espana s.a. - magaldrato - gel oral - 2.000 mg - magaldrato 2000 mg - magaldrato